NASDAQ:ZYNE Zynerba Pharmaceuticals (ZYNE) Stock Forecast, Price & News $1.34 0.00 (0.00%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$1.32▼$1.3450-Day Range$0.33▼$1.3952-Week Range$0.25▼$1.40Volume603,578 shsAverage Volume662,366 shsMarket Capitalization$72.28 millionP/E RatioN/ADividend YieldN/APrice Target$1.11 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zynerba Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside17.2% Downside$1.11 Price TargetShort InterestHealthy0.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$64,033 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.84) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.16 out of 5 starsMedical Sector942nd out of 963 stocksPharmaceutical Preparations Industry450th out of 458 stocks 1.1 Analyst's Opinion Consensus RatingZynerba Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.11, Zynerba Pharmaceuticals has a forecasted downside of 17.2% from its current price of $1.34.Amount of Analyst CoverageZynerba Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the outstanding shares of Zynerba Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverZynerba Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zynerba Pharmaceuticals has recently increased by 286.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZynerba Pharmaceuticals does not currently pay a dividend.Dividend GrowthZynerba Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYNE. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Zynerba Pharmaceuticals this week, compared to 1 article on an average week.Search Interest5 people have searched for ZYNE on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows3 people have added Zynerba Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynerba Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,033.00 in company stock.Percentage Held by Insiders13.04% of the stock of Zynerba Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.23% of the stock of Zynerba Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynerba Pharmaceuticals is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynerba Pharmaceuticals is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZynerba Pharmaceuticals has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zynerba Pharmaceuticals (NASDAQ:ZYNE) StockZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.Read More ZYNE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYNE Stock News HeadlinesSeptember 19, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Coverage Initiated at StockNews.comSeptember 14, 2023 | finance.yahoo.comInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncSeptember 24, 2023 | Legacy Research (Ad)ATTENTION: Digital Dollar Could Send this $0.25 Play SkyrocketingIn just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.September 14, 2023 | finance.yahoo.comZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumSeptember 14, 2023 | americanbankingnews.comZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Short Interest Up 286.8% in AugustAugust 16, 2023 | msn.comHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)August 15, 2023 | finance.yahoo.comIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?August 14, 2023 | marketwatch.comZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNESeptember 24, 2023 | Legacy Research (Ad)ATTENTION: Digital Dollar Could Send this $0.25 Play SkyrocketingIn just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.August 14, 2023 | markets.businessinsider.comCrude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike HigherAugust 14, 2023 | technews.tmcnet.comZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 14, 2023 | finance.yahoo.comHARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.July 25, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces New Date for Reconvened Annual MeetingJune 29, 2023 | finance.yahoo.comZynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?June 28, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Further Adjournment of Annual MeetingJune 20, 2023 | finance.yahoo.comZynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferenceJune 13, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Partial Adjournment of Annual MeetingMay 17, 2023 | bizjournals.comMain Line CBD drug developer plans reverse stock split to boost share priceMay 15, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsMay 15, 2023 | investing.comZynerba Pharma (ZYNE) Earnings Dates & ReportsMay 15, 2023 | msn.comZynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The DetailsMay 15, 2023 | finance.yahoo.comZynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsMay 15, 2023 | finance.yahoo.comZynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsApril 18, 2023 | marketwatch.comFibromyalgia Treatment Drug Market Overview and Scope By 2030April 14, 2023 | marketwatch.comZynerba Pharmaceuticals Presents Data on Zygel(TM) at the 55th Gatlinburg ConferenceApril 12, 2023 | finance.yahoo.comZynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg ConferenceApril 5, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg ConferenceSee More Headlines Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYNE Company Calendar Last Earnings8/14/2023Today9/24/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZYNE CUSIPN/A CIK1621443 Webwww.zynerba.com Phone(484) 581-7505FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.11 High Stock Price Forecast$1.11 Low Stock Price Forecast$1.11 Forecasted Upside/Downside-17.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.03% Return on Assets-72.62% Debt Debt-to-Equity RatioN/A Current Ratio3.43 Quick Ratio3.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book1.33Miscellaneous Outstanding Shares53,940,000Free Float46,905,000Market Cap$72.28 million OptionableOptionable Beta1.33 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Armando Anido MBA (Age 65)Chairman & CEO Comp: $934.53kMs. Terri B. Sebree (Age 65)Pres Comp: $729.15kMr. James E. Fickenscher (Age 59)CFO & VP of Corp. Devel. (Leave of Absence) Comp: $607.62kMr. Kenneth T. Jones (Age 59)VP, Corp. Controller & Interim CFO Mr. Albert P. Parker II (Age 57)Chief Legal Officer & Corp. Sec. Mr. Joseph ApostolicoVP of HRMore ExecutivesKey CompetitorsAffimedNASDAQ:AFMDKinnate BiopharmaNASDAQ:KNTEG1 TherapeuticsNASDAQ:GTHXAdicet BioNASDAQ:ACETEliem TherapeuticsNASDAQ:ELYMView All CompetitorsInsiders & InstitutionsArmando AnidoSold 17,830 sharesTotal: $23,713.90 ($1.33/share)Terri B SebreeSold 12,401 sharesTotal: $16,493.33 ($1.33/share)James E FickenscherSold 8,998 sharesTotal: $11,967.34 ($1.33/share)Brian RosenbergerSold 6,411 sharesTotal: $8,526.63 ($1.33/share)Kenneth T JonesSold 2,505 sharesTotal: $3,331.65 ($1.33/share)View All Insider TransactionsView All Institutional Transactions ZYNE Stock - Frequently Asked Questions Should I buy or sell Zynerba Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares. View ZYNE analyst ratings or view top-rated stocks. What is Zynerba Pharmaceuticals' stock price forecast for 2023? 4 Wall Street analysts have issued 12-month target prices for Zynerba Pharmaceuticals' shares. Their ZYNE share price forecasts range from $1.11 to $1.11. On average, they expect the company's share price to reach $1.11 in the next year. This suggests that the stock has a possible downside of 17.2%. View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts. How have ZYNE shares performed in 2023? Zynerba Pharmaceuticals' stock was trading at $0.53 at the start of the year. Since then, ZYNE shares have increased by 152.8% and is now trading at $1.34. View the best growth stocks for 2023 here. Are investors shorting Zynerba Pharmaceuticals? Zynerba Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 240,600 shares, an increase of 286.8% from the August 15th total of 62,200 shares. Based on an average daily volume of 769,300 shares, the short-interest ratio is currently 0.3 days. View Zynerba Pharmaceuticals' Short Interest. When is Zynerba Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ZYNE earnings forecast. How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. What ETF holds Zynerba Pharmaceuticals' stock ? Amplify Seymour Cannabis ETF holds 220,858 shares of ZYNE stock, representing 0.30% of its portfolio. What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU). When did Zynerba Pharmaceuticals IPO? (ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. What is Zynerba Pharmaceuticals' stock symbol? Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE." Who are Zynerba Pharmaceuticals' major shareholders? Zynerba Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.38%), Renaissance Technologies LLC (1.29%), Bernardo Wealth Planning LLC (0.15%), Wells Fargo & Company MN (0.14%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher, Kenneth T Jones, Pamela Stephenson and Terri B Sebree. View institutional ownership trends. How do I buy shares of Zynerba Pharmaceuticals? Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zynerba Pharmaceuticals' stock price today? One share of ZYNE stock can currently be purchased for approximately $1.34. How much money does Zynerba Pharmaceuticals make? Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $72.28 million. The company earns $-35,040,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. How can I contact Zynerba Pharmaceuticals? Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com. This page (NASDAQ:ZYNE) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.